Equity Overview
Price & Market Data
Price: $33.80
Daily Change: +$3.10 / 9.17%
Range: $30.75 - $33.80
Market Cap: $2,179,524,096
Volume: 1,294,301
Performance Metrics
1 Week: 34.13%
1 Month: 5.47%
3 Months: -24.12%
6 Months: -27.92%
1 Year: -2.30%
YTD: -16.58%
Company Details
Employees: 188
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.